CYP2C19
The company is seeing its CYP2C19 test adopted broadly as it prepares to submit a new application to the FDA for an assay targeting neurodegenerative disease.
Neurologists treating patients who present with a small stroke or transient ischemic attack are now able to get PGx results to inform their prescription of Plavix within 24 hours.
UK's NICE Recommends Genetic Testing for Therapy Selection in Stroke Patients
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
PGx-Guided Dosing Can Lead to Faster Therapeutic Blood Levels of Antidepressants
A randomized controlled trial compared cytochrome P450 genotype-based dosing of tricyclic antidepressants to usual care among patients with depression.
Genomadix Gets FDA 510(k) Clearance for PCR System, CYP2C19 Test
Canada's Genomadix, formerly known as Spartan Bioscience, expects to now commercialize the system and test in the US to guide therapy decisions.